Professor, Departments of Psychiatry & Biobehavioral Sciences and Pediatrics
Director, Division of Child and Adolescent Psychiatry
B.S. Oberlin College and Columbia University
M.D. State University of New York, Downstate Medical Center
Internship Internal Medicine Internship, Pacific Medical Center, San Francisco, CA
Residency Cedars-Sinai Medical Center, Los Angeles, CA
Fellowship Family, Child and Adolescent Psychiatry Fellowship, Cedars-Sinai Medical Center, Los Angeles, CA
Fellowship Child Psychiatry Fellowship, The Johns Hopkins Hospital, Baltimore, MD
Dr. Grob has been the Director of the Division of Child and Adolescent Psychiatry at Harbor-UCLA Medical Center since 1993. His clinical interests include mood and anxiety disorders, as well as the self-medication hypothesis of substance abuse as it applies to substance abuse. He has published in the professional literature on a variety of topics, including adolescent development and psychopathology, cross-cultural models of substance use and misuse and the history of hallucinogens in psychiatry. His research has included the first FDA approved Phase 1 study of the physiological and psychological effects of MDMA (3,4-methlyenedioxymethamphetamine), a multi-national, collaborative study of the Amazonian plant hallucinogen decoction, ayahuasca, in Brazil and a pilot investigation of the safety and efficacy of psilocybin in the treatment of anxiety in adult patients with advanced-stage cancer.
Grob, C.S. and Dobkin de Rios, M.: Adolescent Drug Use in Cross Cultural Perspective, Journal of Drug Issues, 22:121- 138, 1992.
Grob, C.S,Poland, R.E, Chang, L. and Ernst, T: Psychobiologic effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans: methodological considerations and preliminary data, Behavioural Brain Research, 73:103-107, 1996.
Grob, C.S, McKenna, D.J, Callaway, J.C, Brito, G.S, Neves, E.S, Oberlaender, G, Saide, O.L, Labigalini, E, Tacla, C, Miranda, C.T, Strassman, R.J. and Boone, K.B: Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil, J Nervous and Mental Disease, 184:86-94, 1996.
Grob, C.S: Deconstructing ecstasy: The politics of MDMA research. Addiction Research 8:549-588, 2000
Grob, C.S. andPoland, R.E: MDMA: in J.H. Lowinson, P. Ruiz, R.B. Millman and J.G. Langrod (Eds.), Substance Abuse: A Comprehensive Textbook, 4th Edition, Phildadelphia: Williams and Wilkins, pp. 274-286, 2005.
Doering-Silveira, E, Grob, C.S, Dobkin de Rios, M, Lopez, E, Alonso, L.B, Tacla, C, Brito, G.S, Castello, O. and Da Silveira, D.X. Ayahuasca in adolescence: a preliminary psychiatric assessment. Journal of Psychoactive Drugs 37:129-133, 2005.
Grob, C.S. The enigma of ecstasy: implications for youth and society. Adolescent Psychiatry 29:97-117, 2005.
Grob, C.S. The use of psilocybin in patients with advanced cancer and existential anxiety: in Winkelman, M., and Roberts, T. (Eds.) Psychedelic Medicine: New Evidence for Hallucinogens as Treatments.Westport,CT, Praeger/Greenwood, vol. 1, pp.205-216, 2007.
Griffiths, R.R. and Grob, C.S. Hallucinogens as medicine. Scientific American 303: 77-79, 2010.
Grob, C.S, Danforth, A.L, Chopra, G.S, Hagerty, M.C, McKay, C.R, Halberstadt, A.L. and Greer, G.R. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry 68(1):71-78, 2011.